Introduction Executive Summary Glucagon-Like Peptide 1 Receptor Agonists: Overview • Structure • Mechanism of Action Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Glucagon-Like Peptide 1 Receptor Agonists – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • Glucagon-Like Peptide 1 Receptor Agonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends Glucagon-Like Peptide 1 Receptor Agonists Collaboration Deals • Company-Company Collaborations (Licensing / Partnering) Analysis • Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) • Comparative Analysis Tirzepatide: Eli Lilly and Company • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis IBI-362: Innovent Biologics • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) • Comparative Analysis Drug name: Company name • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Pre-clinical and Discovery Stage Products • Comparative Analysis Exenatide/insulin sublingual: Biolingus • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Glucagon-Like Peptide 1 Receptor Agonists Key Companies Glucagon-Like Peptide 1 Receptor Agonists Key Products Glucagon-Like Peptide 1 Receptor Agonists- Unmet Needs Glucagon-Like Peptide 1 Receptor Agonists- Market Drivers and Barriers Glucagon-Like Peptide 1 Receptor Agonists- Future Perspectives and Conclusion Glucagon-Like Peptide 1 Receptor Agonists Analyst Views Glucagon-Like Peptide 1 Receptor Agonists Key Companies Appendix

Table 1 Total Products for Glucagon-Like Peptide 1 Receptor Agonists Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Eli Lilly and Company • Innovent Biologics • Novo Nordisk • AstraZeneca • Biolingus • D and D Pharmatech • Terns Pharmaceuticals • i2O Therapeutics